QC Medica

What QC Medica does

QC Medica LLP is a UK-based health economics and outcomes research (HEOR) consultancy founded in 2016 and headquartered in Liverpool. The firm delivers a unified five-pillar service portfolio covering Health Economics (custom economic and budget impact models, adaptation of global models for local HTA submissions), Evidence Development (real-world evidence generation from EMRs, claims databases, registries, and bespoke surveys), Evidence Synthesis (systematic literature reviews, network meta-analyses, global value dossier development, HTA and regulatory submission support), Strategy & Insight (product value assessment, advisory boards, medical affairs planning), and Training Courses (bespoke 2-day HEOR workshops). Underlying delivery relies on senior consultant expertise rather than proprietary technology platforms, with services executed through bespoke client engagements.

The firm is led by Managing Director Paul G. Martin (PhD, MBA, MPH, BCMAS) with two decades of European biotech leadership across Johnson & Johnson, Centocor, Boston Scientific, Pacira Biosciences, and others; Antony P. Martin (PhD, University of Liverpool) as Director of HEOR & RWE; and Rachel Houten as Head of Health Economics & HTA, drawing on prior NICE and LRiG experience. The team of six combines more than 40 years of pharmaceutical, academic, and consulting experience.

QC Medica operates as a private Limited Liability Partnership (OC423509) with no disclosed external institutional investors or parent entity. Revenue is generated through professional-services fees on bespoke consulting engagements plus workshop-based training income. The go-to-market is sales-led and event-driven, anchored on direct enterprise relationships with pharmaceutical, biotech, and medical device companies (including Roche, Clovis Oncology, Leo Pharma, and The Medicines Company) as well as government health bodies (Welsh Government), supported by conference participation at ISPOR and HTAi, peer-reviewed publications in journals such as Value in Health and the Journal of Medical Economics, and academic partnerships with the University of Liverpool and Liverpool John Moores University.

Name

QC Medica

Legal name

QC Medica LLP

Website

https://qcmedica.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

QC Medica LLP is a UK-based health economics and outcomes research consultancy founded in 2016, delivering bespoke HEOR modeling, real-world evidence generation, evidence synthesis, HTA submissions, and training to pharmaceutical, biotech, medical device companies, and government health bodies.

Ownership category

akta.pro rank

Product category

Health Economics & Outcomes Research Consulting

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

akta.pro secondary industry

Cost of Care, Spend Analytics & Financial Performance Management (HLACAHAJ)

Keywords

• Health economics consulting
• Outcomes research services
• Health technology assessment
• Real-world evidence generation
• Pharmacoeconomic modelling

Headquarters

HQ city

Liverpool

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Health Economics Consulting Services: Professional consulting services providing health economic models, HTA submissions, evidence development and synthesis, and strategic advisory services to pharmaceutical, biotech, and medical device companies.
2. Training and Education Services: Bespoke interactive training and education sessions on health economics, HTA, modelling, and related topics delivered as 2-day expert workshops.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

QC Medica is a health economics and outcomes research (HEOR) consultancy that provides bespoke health economic and budget impact modelling, real-world evidence generation, evidence synthesis (systematic reviews, network meta-analyses, value dossiers), HTA submission support, strategic market access and medical affairs advisory, and interactive HEOR training courses. Services are delivered by a multidisciplinary team to pharmaceutical, biotechnology, medical device and healthcare organisations in the UK and internationally.

Product overview

QC Medica is a health economics and outcomes research (HEOR) consultancy offering a unified portfolio of services rather than a software product. The core offerings include Health Economics (economic modelling and budget impact analysis), Evidence Development (real world evidence generation through EMRs, claims databases, registries), Evidence Synthesis (systematic reviews, value dossier development, HTA submissions), Strategy & Insight (product value assessment, advisory boards, medical affairs), and Training Courses (HEOR education). These services are delivered by a multidisciplinary team combining over 40 years of experience in pharmaceutical industry, academia, and consulting.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Economics Services Health economics consulting delivering health economic and budget impact models, adaptation of global/core models for local HTA submissions, early-stage models, burden of illness models, and expert review and validation of modelling approaches for pharmaceutical, biotech and medical device clients.
• Evidence Development Services Real-world evidence generation through analysis of electronic medical records, claims databases, registries and bespoke surveys, including retrospective and prospective studies, qualitative and quantitative surveys for pharmaceutical and medical device clients.
• Evidence Synthesis Services Systematic literature reviews, network meta-analyses, global value dossier development, HTA and regulatory submission support, and development of internal and external communication tools for pharmaceutical and biotech clients.
• Strategy & Insight Services Early product value assessment, advisory board organisation, expert review of evidence development plans, HTA submission material review, strategic medical affairs planning, medical information materials, and multi-channel medical education solutions for pharmaceutical and biotech clients.
• Training Courses Bespoke interactive HEOR and medical education training courses covering health economics, HTA, modelling, medical affairs, critical appraisal, systematic literature reviews, RWE and strategic medico-marketing, delivered on client sites or in York, UK, in person or virtually.

Quantifiable outcome

• 11-fold increase in BRCA testing observed following high-profile publications in one UK catchment area
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• NHS EnglandminorOthersQC Medica has worked with NHS England and NHS trusts on various health economics projects, including analysis of NHS Resolution data for informed consent litigation research published in the British Journal of Surgery.
• University of LiverpoolcoreStrategic or Co-development PartnerActive collaboration with University of Liverpool including hosting MBA student projects, academic research collaborations, and team members with academic affiliations. University leadership includes Director and Reader in Health Economics providing peer endorsement.
• Liverpool John Moores UniversityminorStrategic or Co-development PartnerCollaboration with Liverpool John Moores University researchers on the COMPAT study examining outcomes for people with complex mental health needs.
• Cheshire & Wirral Partnership NHS Foundation TrustminorOthersResearch collaboration examining alternative care pathways for people with complex mental health needs.
• NICE (National Institute for Health and Care Excellence)coreStrategic or Co-development PartnerExtensive engagement with NICE including HTA submissions, participation in consultations, and team members with direct NICE experience. Contributed to NICE Methods Consultation discussions and real-world evidence framework developments.
• ISPORminorOthersActive participation in ISPOR conferences and workshops as presenters and discussants. Team members engage with ISPOR professional society for health economics and outcomes research.
• HTAiminorOthersActive participation in HTAi conferences and annual meetings with research presentations on topics including NICE patient access schemes.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Tolley Health Economics: UK-based health economics consultancy providing modeling, systematic review, and HTA support. Comparable UK HTA focus and HEOR service offerings.
• Mtech Access: UK-based health economics and market access consultancy offering health economic modeling, evidence generation, and HTA support. Strong comparable given overlapping service lines and UK-centric client base.
• Wickenstones: Specialist HEOR and market access consultancy serving pharma and biotech clients with health economic evidence and value communication services. Closely comparable boutique consultancy model.
• Pharmerit International (OPEN Health): HEOR and market access consultancy now part of OPEN Health, providing health economic modeling, evidence synthesis, and RWE generation. Comparable specialized service portfolio and pharma/biotech client base.
• BresMed Health Solutions: UK-based HEOR and market access consultancy providing health economic modeling, evidence synthesis, and HTA submission support. Directly comparable given similar UK HTA orientation and service portfolio.
• Putnam Associates: Specialist HEOR and market access consulting firm serving pharmaceutical and biotech clients globally. Highly comparable as a boutique consultancy focused on health economic modeling, HTA submissions, and value communication.
• Cogentia Healthcare Consulting: UK health economics and market access consultancy providing health technology assessment, evidence generation, and value demonstration services. Comparable niche consultancy targeting pharma and NHS clients.

Broad incumbents

• Parexel International: Global CRO with significant HEOR and market access capabilities. Comparable end-to-end service offering but operating at much larger scale across clinical, regulatory, and commercial functions.
• IQVIA: Global clinical research and HEOR powerhouse providing real-world evidence, health economics, and market access services. Comparable HEOR capabilities but at vastly larger scale and as part of full-service CRO.
• Evidera (PPD): Large-scale HEOR and real-world evidence consulting division within PPD/Thermo Fisher Scientific. Offers overlapping health economic modeling, evidence synthesis, and market access services as part of a broader CRO portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/qc-medica-llp

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QC Medica